Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

DASL-HiCaP is a randomised phase 3 study aiming to demonstrate that the addition of a new oral hormonal therapy, darolutamide, to the standard radiation therapy and testosterone suppression, improves the outcomes of men with localised high-risk prostate cancer.

Primary Sponsor

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre

Accrual Target

1100

Final Accrual

1100

Trial Chairperson

Prof Christopher Sweeney and Assoc/Prof Tamim Niazi

Trial Contact

dasl.study@sydney.edu.au

Clinical Trial Registration

Related Post

DECREASE trial into prostate cancer
8 July, 2025

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial

TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE

Geoff Zipper - aka Swamp - on the Kokoda Trail
26 June, 2025

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

LATEST NEWS: 26 June 2025 He may be 76